Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $10.4 million.

  • Contineum Therapeutics' Total Liabilities rose 7872.89% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 7872.89%. This contributed to the annual value of $14.8 million for FY2024, which is 15922.48% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Total Liabilities of $10.4 million as of Q3 2025, which was up 7872.89% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Total Liabilities registered a high of $14.8 million during Q4 2024, and its lowest value of $3.9 million during Q2 2024.
  • Its 3-year average for Total Liabilities is $9.0 million, with a median of $8.5 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Contineum Therapeutics' Total Liabilities was 19849.43% (2025), while the steepest drop was 7872.89% (2025).
  • Contineum Therapeutics' Total Liabilities (Quarter) stood at $5.7 million in 2023, then surged by 159.22% to $14.8 million in 2024, then dropped by 29.8% to $10.4 million in 2025.
  • Its Total Liabilities was $10.4 million in Q3 2025, compared to $11.5 million in Q2 2025 and $13.5 million in Q1 2025.